Under construction – not a live service
Sign in
CompletedPhase 1

Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.

Key facts

Phase
Phase 1

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Trial details

Who runs it
Bioprojet Pharma
Trial code
EU 2023-503945-78-00
Record updated
26 July 2024